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Abstract
Background: To examine the differences in menopausal hormone therapy (MHT) use and user
profiles among women in Germany before and after the communication of the Women's Health
Initiative (WHI) trial and other study results concerning the risks and benefits of MHT.
Methods: Current MHT use was ascertained in two periodic German national health surveys
conducted in 1997–1999 and 2003–2004. MHT prevalence and user profiles were assessed within
each survey. The association of the survey period (2003–2004 vs. 1997–1999) with current MHT
use was analyzed in weighted multivariable logistic regression (MLR) models, pooling data from
both surveys.
Results: The overall prevalence of current MHT use decreased by 40.2% from 16.9% of the sample
in 1997–1999 to 10.1% in 2003–2004. The difference in prevalence between surveys varied with
age decade with the smallest decreases among women 60–69 years of age (20.3% vs. 18.5%),
compared to women of younger and older age groups (40–49: 10.7% vs. 3.9%; 50–59: 36.3% vs.
21.3%; 70–79: 5.7% vs. 3.2%). Variables independently associated with higher current MHT use in
both health surveys included age category (curvilinear relationship with highest use among women
50–59 years) and residence in West vs. East Germany. A higher social status, lower body mass
index, and more health-conscious behaviour were significantly associated with higher current MHT
use in the 1997–1999 survey, but these associations were not found in the later survey. MLR
analyses confirmed a significant decline in MHT use between the 1997–1999 and 2003–2004
surveys, however, the effect was modified by social status and was not significant among lowest
social-status women.
Conclusion: Current MHT use considerably declined among women in Germany between the
pre- and post-WHI era. A convergence of current MHT use among women of higher social status
with pre-existing patterns of use among lower social-status women suggests that MHT in Germany
is now less likely to be used for health promotion.
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Background
During the past two decades menopausal hormone ther-
apy (MHT, the term used for both estrogen therapy and
estrogen plus progestin therapy) has been widely pro-
posed and prescribed for postmenopausal women, not
only for the relief of menopausal symptoms, but also for
the prevention of cardiovascular diseases and osteoporo-
sis in later life. Such advice to women was based on a
wealth of supporting results from preclinical as well as
observational clinical and epidemiological studies,
although confirmatory data from randomized clinical tri-
als (RCTs) were still lacking or not based on hard clinical
endpoints [1,2]. Some experts kept advising caution in
view of limited evidence [3]. However, it was not before
the publication of results from two RCTs, the Heart and
Estrogen/Progestin Replacement Study (HERS) in 1998
[4] and the combined estrogen plus progestin therapy arm
of the Women's Health Initiative randomized controlled
trial (EPT-WHI) in 2002 [5] as well as the large observa-
tional Million Women Study (MWS) in 2003 [6] that this
position gained widespread attention among medical
experts and health care officials [7,8]. Ever since, studies
from the United States [9-16] and various other European
countries [17-24], including Germany [25,26], have con-
sistently reported a substantial decline in MHT use.
Up to now, few studies have examined changes in user
profiles with respect to socio-demographic and co-mor-
bidity patterns at a nationally representative level
[15,19,23]. In the present study, we have analyzed differ-
ences in the prevalence and correlates of current MHT use
among women in Germany, based on data from two peri-
odic national health surveys conducted in 1997–1999
and 2003–2004.
Methods
Study design and population
The German National Health Interview and Examination
Survey 1998 and the German National Health Telephone
Survey 2004 were conducted by the Robert Koch-Institute
between October 1997 and March 1999 (1997–1999 sur-
vey) and between September 2003 and March 2004
(2003–2004 survey). The designs, sampling frames and
study protocols of both surveys have been previously
described in detail [27,28]. In brief, two stage sampling
procedures were applied in both surveys. In the 1997–
1999 survey, a sample of German communities (80 in
West Germany and 40 in East Germany) representing
community size and structure in Germany was drawn at
the first stage. Age- (5-year-intervals) and sex-stratified
random samples of adult residents 18–79 years of age
were then drawn from local population registries in pro-
portion to the age and gender structure of the German
adult population. The final sample included 7124 resi-
dents (3450 men; 3674 women) at a response rate of
61.4%. In the 2003–2004 survey, a pool of about 45,000
telephone numbers from complete listings of conven-
tional telephone extensions belonging to private house-
holds in Germany was randomly generated, applying the
Häder-Gabler method [29]. This method assures that
households with unregistered telephone extensions are
included in the 'target sample' of telephone surveys. Ran-
dom sampling at the individual level was achieved by the
'next-birthday-method', i.e. only the adult whose birthday
is coming up next to the date of first contact to the respec-
tive household is included in the target sample. Alto-
gether, 56.1% of contacted persons 18 years of age and
older completed the survey (3376 men; 3965 women).
Menopause is most likely to occur between 40 and 60
years [30], and women in Germany tend to start MHT at a
relatively young age [31]. Given a common upper age
range of 79 years in the two surveys, the present analysis
is therefore based on women who were 40–79 years at the
time of participation. Thus, the study population includes
a total of 2248 women participating in the 1997–1999
survey and 2215 women participating in the 2003–2004
survey.
Both surveys were approved by the Federal Office for the
Protection of Data. Participants were informed in detail
about the study objectives, interview and examination
procedures, as well as pseudonymized record keeping and
data analyses. Persons participating in the 1997–1999
survey gave written informed consent prior to the inter-
view and examination, oral informed consent was sought
in survey 2003–2004.
Data assessment
In the 1997–1999 survey, information on health behav-
iour and socio-demographic background was collected by
means of a self-administered questionnaire. Measures of
height and weight, medical history and information on
the use of medication were obtained as part of a highly
standardized computer-assisted health interview and
examination, conducted by specifically trained study phy-
sicians and assisting technical staff [27]. Use of any medi-
cation within the last seven days before the medical
interview, including prescription drugs and over-the-
counter medications, was assessed using a standardized
drug use questionnaire. Details on the use of the medica-
tion, such as daily dose, route of application, and dura-
tion of use were documented. Participants were asked to
bring original containers or package inserts to the exami-
nation site for the purpose of verification. Specific ATC-
(Anatomical Therapeutic Chemical) codes were assigned
to all reported medications. Based on this information, we
were able to identify current MHT users as women cur-
rently taking sex hormone preparations used exclusively
for MHT (ATC-codes G03C, G03D, G03E, G03F, G03HB).BMC Women's Health 2007, 7:19 http://www.biomedcentral.com/1472-6874/7/19
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Data collection in the 2003–2004 survey was based on a
highly standardized computer-assisted telephone inter-
view (CATI) [28]. The definition of MHT use was based on
a sequence of two questions: 1) Have you ever taken hor-
mone preparations in connection with the menopause? and 2)
Are you currently taking hormone preparations? Women
answering in the affirmative to both questions were
defined as 'current MHT users'; if only question 1 was
affirmed, women were defined as past MHT users.
Duration of MHT was assessed based on an ordinal scale
('≤ 1 year'; '1–3 years'; '> 3 years') in the 1997–1999 sur-
vey, as opposed to asking the number of years in the
2003–2004 survey. We therefore used '> 3 years' as a com-
mon definition of long-term MHT among current users.
Neither survey questionnaire included a specific question
to measure recent uptake of MHT. Using the available
information, we estimated the prevalence of 'new starters'
based on current MHT users who reported to have used
MHT for up to one year.
Body mass index (BMI) in the 2003–2004 survey was
computed from self-reported measures of weight and
height, with adjustment for potential misclassification
bias [32]. Apart from MHT use and BMI, only variables
based on identical questions in both surveys were
included in the analysis. A composite social-status index
was computed, integrating educational level, household
income and profession as previously described [33].
Scores from 1–7 were attributed to each of the compo-
nents and the sum of the scores was calculated ranging
from a possible minimum of 3 to a maximum of 21. Cat-
egories of social status were defined lower (3–8), interme-
diate (9–14), and upper (15–21) [33]. While based on
identical questions to collect information on the individ-
ual components, the construct variable was adjusted to
societal changes, namely income inflation and improve-
ments in people's education. This assures a high degree of
standardization with respect to data collection, as well as
comparability of the construct over time (Robert Koch-
Institute, unpublished data). A definition of pre-existing
medical conditions, such as diabetes mellitus, hyperten-
sion, and hyperlipidemia was based on the question: 'Has
a doctor ever told you that you have one of the following condi-
tions?'. Pre-existing cardiovascular disease (CVD) included
a history of coronary heart disease, angina, congestive
heart failure, previous myocardial infarction or stroke.
Statistical analysis
A weighting factor was computed from survey-specific
weighting factors adjusting for deviations in demographic
characteristics (age, sex, residence in West or East Ger-
many and level of urbanity) between the study popula-
tions and official population statistics at the time of the
specific surveys [28,34] as well as at a point in time (2003)
that served as a common standard for both surveys.
We used descriptive statistics to assess the main character-
istics of the study population within each survey. The
weighted prevalence of MHT and the distribution of
socio-demographic and health-related co-variables were
compared between the two surveys, applying chi-square
and t-tests as appropriate. Survey specific multivariable
logistic regression (MLR) analyses with current MHT sta-
tus as the dependent variable and all other study charac-
teristics as independent variables were performed to
identify MHT user profiles within the two surveys. In
order to estimate the independent effect of the survey
period on current MHT use, a full model was fitted, pool-
ing data from both surveys and adding the survey period
(2003–2004 survey vs. 1997–1999 survey) as the inde-
pendent variable of main interest. Socio-demographic
characteristics, lifestyle variables and pre-existing morbid-
ity as well as their first order interactions with the survey
period were included as co-variables. As the interaction
between survey period and social status was highly signif-
icant, the effect of the survey period on current MHT use
was estimated in separate multivariate logistic regression
models stratified by social status.
All statistical analyses were performed with SPSS statistical
software (release 15.0). The composed weighting factor
was used throughout all calculations. We present
weighted results, unless stated otherwise. A probability
level of p < 0.05 based on two-sided tests was considered
statistically significant. No adjustments for multiple test-
ing were made, due to the focus on survey effect.
Results
Characteristics of the study populations
Main characteristics of the study population are shown in
Table 1. Survey populations were similar with respect to
age, BMI, residence in West vs. East Germany, and selected
pre-existing medical conditions, except for hyperlipi-
demia. Compared to women participating in the 1997–
1999 survey, women surveyed in 2003–2004 were more
likely to be current or former smokers and to be more
physically active. Study populations also differed with
respect to a higher proportion of women with lowest and
highest social status in the more recent survey.
Current MHT use and user profiles in the two national 
health surveys
A total of 419 (absolute number, unweighted) women
were current MHT users in the 1997–1999 survey. Among
2003–2004 participants, 260 women were current and
392 were past MHT users (absolute number, unweighted).
The overall weighted prevalence of current MHT use
decreased by 40.2% from 16.9% of the sample in 1997–BMC Women's Health 2007, 7:19 http://www.biomedcentral.com/1472-6874/7/19
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1999 to 10.1% in 2003–2004 (Table 1). In both national
health surveys, the prevalence of current MHT users was
curvilinearly related to age, with the highest rates among
50–59-year-old women (Figure 1 and Table 2). The differ-
ence in prevalence between surveys varied with age cate-
gory. Absolute decreases as well as the percentage
difference were largest among women 40–49 and 50–59
years of age as opposed to almost no difference among
women 60–69 years of age (Table 2). A relative decrease
of about 44% in current MHT use among women 70–79
years of age (Table 2) was attributable to differences
among women 75 years of age and older (Table 2 and Fig-
ure 1). However, the number of current MHT users within
this age group was very small (n = 18) in the 1997–1999
survey, and no woman in this 2003–2004 survey reported
current use of MHT.
The prevalence of 'new starters' declined significantly by
78% between survey periods (Table 1). A smaller percent-
Table 1: Descriptive characteristics of women populations surveyed in German national health surveys before (1997–1999) and after 
(2003–2004) the publication of the EPT-WHI trial results
1997–1999 survey 2003–2004 survey p-value
Sample size (unweighted total n) 2284 (2248) 2362 (2215)
Continuous variables, mean ± SD
Age, years 59.8 ± 12.0 60.0 ± 12.5 0.437
BMI, kg/m2 27.8 ± 5.1 27.6 ± 5.2 0.566
Nominal and ordinal variables, n (%)
Residence in former West Germany 1762(77.1) 1841(77.9) 0.515
Social status
Lower 691(31.8) 848(36.9) < 0.001
Intermediate 1115(51.4) 1003(43.7)
Upper 364(16.8) 446(19.4)
Smoking status
Smoker 405(18.4) 485(20.5) < 0.001
Ex-smoker 349(15.9) 538(22.8)
Non-smoker 1447(65.7) 1339(56.7)
Physical activity
0 hrs/wk 1277(58.4) 1135(48.6) < 0.001
< 1 hrs/wk 268(12.2) 232(9.9)
1–2 hrs/wk 377(17.2) 503(21.5)
> 2 hrs/wk 266(12.2) 466(19.9)
Pre-existing medical conditions (yes vs. no)
Diabetes 217(9.6) 228(9.7) 0.891
Hypertension 868(38.2) 950(40.4) 0.128
Hyperlipidemia 751(33.0) 881(37.5) 0.001
CVD 385(16.9) 355(15.3) 0.124
Current MHT use#, n (%) 386(16.9) 238(10.1) < 0.001
≤ 1 year (new starters) 71(3.1) 16(0.7) < 0.001
1–3 years 81(3.5) 31(1.3) < 0.001
> 3 years (long-term users) 230(10.1) 189(8.0) 0.014
All results are weighted to the distribution of main demographic characteristics (age, sex, residence in West or East Germany and level of urbanity) 
in the German population according to official population statistics at the time of the survey as well as in 2003.
p-values are based on t-tests for continuous variables or χ2-tests for dichotomous variables.
EPT-WHI = combined estrogen plus progestin therapy arm of the Women's Health Initiative randomized controlled trial; BMI = Body mass index; 
CVD = cardiovascular disease; hr(s)/wk = hour(s)/week; MHT = menopausal hormone therapy.
# Information for duration of MHT use was missing in 4 users in the 1997–1999 survey and 2 users in the 2003–2004 survey.
Age-classified current MHT use prevalence in the two Ger- man national health surveys conducted before (1997–1999)  and after (2003–2004) the EPT-WHI study Figure 1
Age-classified current MHT use prevalence in the two Ger-
man national health surveys conducted before (1997–1999) 
and after (2003–2004) the EPT-WHI study. MHT = Meno-
pausal hormone therapy. EPT-WHI = combined estrogen 
plus progestin therapy arm of the Women's Health Initiative 
randomized controlled trial. * p < 0.05, ** p < 0.001, com-
pared to age specific prevalence in the 1997–1999 survey.
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age decrease (21%) was observed for the prevalence of
long-term MHT users. However, the proportion of long-
term users among women currently using MHT signifi-
cantly increased by one third from 60.2% in 1997–1999
to 80.1% in 2003–2004 (p < 0.001, data not shown in
Table 1). Among MHT users 60 years and older, the pro-
portion of long-term users increased from 83.6% in
1997–99 to 96.4% in 2003–2004 (data not shown in
Table 1).
Apart from age group, variables independently related to
current MHT use in the 1997–1999 survey included resi-
dence in West Germany, higher social status, lower BMI
and more health-conscious behaviour (Table 2). In the
2003–2004 survey, only associations with age category
and residence in West vs. East Germany persisted. In par-
ticular, higher social status was significantly related to the
prevalence of current MHT use in the earlier survey, but
the association was no longer significant in the more
recent survey (Table 2). This was also true for the preva-
lence of 'new starters' and long-term MHT users (data not
shown). A significant and inverse association between
current MHT use and a medical history of diabetes melli-
tus was observed in the 2003–2004 survey (Table 2).
MHT use was consistently higher in West than East Ger-
many, but the absolute decrease was considerably larger
among women living in the West. Similar patterns of
highest MHT use in 1997–1999 and strongest decreases in
use from 1997–1999 to 2003–2004 were observed in
association with lower BMI, higher social status, higher
level of physical activity, and ex-smoker status (Table 2).
Table 2: Prevalence and determinants of current MHT use in the two surveys conducted before (1997–1999) and after (2003–2004) the 
publication of EPT-WHI trial results
Prevalence % Difference % OR (95% CI)
1997–1999 2003–2004 Absolute Relative 1997–1999 2003–2004
Age, years
40–49 10.7 3.9 -6.8 -63.6 0.20(0.15–0.27) 0.14(0.09–0.21)
50–59 36.3 21.3 -15.0 -41.3 1(Reference) 1(Reference)
60–69 20.3 18.5 -1.8 -8.9 0.56(0.42–0.76) 0.78(0.55–1.09)
70–79 5.7 3.2 -2.5 -43.9 0.13(0.07–0.23) 0.14(0.07–0.31)
Region
West Germany 18.4 10.7 -7.7 -41.8 1.73(1.33–2.25) 1.74(1.15–2.64)
East Germany 11.9 7.9 -4.0 -33.6 1(Reference) 1(Reference)
BMI
< 25 kg/m2 20.5 9.8 -10.7 -52.2 1.79(1.28–2.51) 1.38(0.90–2.11)
25–30 kg/m2 18.8 12.3 -6.5 -34.6 1.70(1.24–2.34) 1.42(0.96–2.10)
> = 30 kg/m2 10.0 7.5 -2.5 -25.0 1(Reference) 1(Reference)
Social status
Lower 9.3 8.1 -1.2 -12.9 1(Reference) 1(Reference)
Intermediate 20.2 11.1 -9.1 -45.0 1.87(1.37–2.55) 0.85(0.61–1.18)
Upper 25.3 9.3 -16.0 -63.2 1.96(1.35–2.86) 0.73(0.48–1.10)
Smoking status
Smoker 18.8 10.9 -7.9 -42.0 1(Reference) 1(Reference)
Ex-smoker 21.5 8.4 -13.1 -60.9 1.00(0.68–1.46) 0.91(0.60–1.38)
Non-smoker 16.1 10.5 -5.6 -34.8 0.86(0.64–1.17) 1.00(0.70–1.43)
Physical activity
0 hrs/wk 13.5 8.5 -5.0 -37.0 1(Reference) 1(Reference)
0–1 hrs/wk 21.6 9.9 -11.7 -54.2 1.49(1.06–2.10) 1.15(0.71–1.88)
1–2 hrs/wk 22.0 11.1 -10.9 -49.5 1.29(0.94–1.76) 0.85(0.58–1.23)
> 2 hrs/wk 25.6 12.7 -12.9 -50.4 1.56(1.10–2.21) 1.02(0.71–1.48)
Pre-existing medical conditions (yes vs. no)
Diabetes 6.4 3.5 -2.9 -45.3 0.74(0.41–1.33) 0.42(0.21–0.87)
Hypertension 14.3 9.9 -4.4 -30.8 1.06(0.80–1.39) 1.07(0.78–1.47)
Hyperlipidemia 17.3 11.4 -5.9 -34.1 1.03(0.79–1.33) 1.13(0.84–1.52)
CVD 9.4 10.1 +0.7 +7.4 0.80(0.51–1.25) 1.02(0.63–1.64)
Odds ratios (OR) and 95% confidence intervals (CI) were obtained from survey specific multivariable regression models with current MHT as the 
dependent variable. Explanatory variables included age (10-year age groups) as well as socio-demographic, behavioural and medical characteristics as 
shown above.
EPT-WHI = combined estrogen plus progestin therapy arm of the Women's Health Initiative randomized controlled trial; BMI = Body mass index; 
CVD = cardiovascular disease; hr(s)/wk = hour(s)/week.BMC Women's Health 2007, 7:19 http://www.biomedcentral.com/1472-6874/7/19
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Impact of survey period on current MHT use among 
women in Germany
Pooling data from both surveys, we estimated the inde-
pendent effect of survey period (2003–2004 vs. 1997–
1999) on current MHT use in a MLR regression model
adjusting for age, BMI, social-status index as well as
health-related characteristics and pre-existing medical
conditions. When first order interactions of co-variables
with the survey variable were added to the full model,
only the interaction with social-status index was highly
significant (p = 0.001). This was also true when age was
added as a dichotomous (< 60 vs. ≥ 60 years) co-variable
(data not shown). Table 3 shows the results of the full
model including the interaction between survey and
social-status index. Altogether 20% of variability in cur-
rent MHT use was explained by the model. As reflected by
the estimates for the survey period and the interaction
between survey period and social-status index, current
MHT use was significantly less likely in 2003–2004 com-
pared to 1997–1999 only among women of higher social
status (Table 3). This finding was confirmed in MLR anal-
yses stratifying by social status; the strength of the associ-
ation between survey period and current MHT use showed
a gradual decrease from highest (OR 0.24, 95% CI 0.15–
0.38) via intermediate (0.44, 0.34–0.58) to lowest (1.01,
0.69–1.49) social-status classification.
Discussion
Main findings
In this analysis of two German national health surveys
conducted before and after the publication of EPT-WHI
results, we found that the overall prevalence of current
MHT use among women aged 40–79 years decreased by
40.2% from 16.9% of the sample in the 1997–1999 sur-
vey to 10.1% in the 2003–2004 survey. Differences were
most pronounced in subgroups of women in which MHT
use was particularly common in the pre-WHI era. These
included women 50–59 years of age, women residing in
Table 3: Odds ratios and 95% confidence intervals for current MHT use in the pooling regression model
β p-value Odds ratios and 95% confidence intervals
Age, years
40–49 -1.767 < 0.001 0.17 (0.13–0.22)
50–59 1(Reference)
60–69 -0.392 < 0.001 0.68(0.54–0.85)
70–79 -2.099 < 0.001 0.12(0.09–0.17)
Region
West Germany 0.540 < 0.001 1.72(1.34–2.20)
East Germany 1(Reference)
Smoking status
Smoker 1(Reference)
Ex smoker -0.071 0.643 0.93(0.69–1.26)
Non-smoker -0.074 0.560 0.93(0.73–1.19)
Physical activity
0 hrs/wk 1(Reference)
0–1 hrs/wk 0.218 0.154 1.24(0.92–1.68)
1–2 hrs/wk 0.151 0.241 1.16(0.90–1.50)
> 2 hrs/wk 0.275 0.039 1.32(1.01–1.71)
Pre-existing medical conditions (yes vs. no)
Diabetes -0.808 0.001 0.45(0.27–0.73)
Hypertension 0.099 0.364 1.10(0.89–1.37)
Hyperlipidemia 0.080 0.436 1.08(0.89–1.33)
CVD 0.012 0.937 1.01(0.75–1.38)
BMI, kg/m2 -0.052 < 0.001 0.95(0.93–0.97)
Social-status index 0.057 0.001 1.06(1.03–1.09)
Survey period#
1997–1999 1(Reference)
2003–2004 0.556 0.076 1.74(0.94–3.22)
Social-status index * survey period -0.107 < 0.001 0.90(0.86–0.94)
Odds ratios (OR) and 95% confidence intervals were obtained from multivariable regression models based on pooled data from both surveys with 
current MHT as the dependent variable and survey period as the main independent variable of interest. Co-variables included all other variables as 
shown above.
#: The OR for the survey period 2003–2004 vs. 1997–1999 is dependent on social-status index and is given by exp (0.556-social-status index*0.107) because 
of the significant interaction of social-status index with survey period. For example, given a low social-status index of 5, the OR for survey period 
2003–2004 vs. 1997–1999 would be calculated to exp (0.556-5*0.107) = 1.02.
MHT = menopausal hormone therapy; CVD = cardiovascular disease; hr(s)/wk = hour(s)/week, BMI = Body mass indexBMC Women's Health 2007, 7:19 http://www.biomedcentral.com/1472-6874/7/19
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West Germany, and women with a lower BMI, more
favourable health-related behaviour or higher social sta-
tus. Apart from age category and residence in Western Ger-
many, none of these characteristics continued to be
associated with current MHT in 2003–2004, resulting in
profound differences in user profiles. In particular, we
observed a levelling of current MHT prevalence (overall
current MHT users as well as 'new starters' and long-term
users) between women of different social status. MLR
analyses based on pooled data from both surveys con-
firmed that differences in current MHT use in 2003–2004
compared to 1997–1999 were modified by social status. A
significant decrease in current MHT use was evident
among women of higher but not of lower social status.
Comparison with previous studies
The observation of a significant decline in MHT use
among women in Germany is in accordance with results
from previous studies conducted after the release of WHI
results in the US [9-16] and various other European coun-
tries [17-24] including a regional study in Germany [26].
Our findings that the overall prevalence of current MHT
among German women dropped to only 10% within 1–2
years after the publication of the EPT-WHI trial results is
very much in accordance with recent reports from the
United Kingdom and Italy [17,18]. A significant reduction
in the prevalence of 'new starters' (women using MHT for
up to one year) as observed here and elsewhere [35] lends
further credence to the assumption, that the release and
communication of study results had a major impact on
MHT use among German women. The prevalence of long-
term current users showed a smaller albeit still significant
decline between surveys, while the relative proportion of
long-term users increased. This probably reflects that
long-term MHT users are less likely to quit MHT in the
post-WHI era, and previous reports from other countries
support this assumption [21,36]. In the present analysis,
the proportion of long-term users among women on cur-
rent MHT was significantly higher among women who
were 60 years and older, compared to those of younger
age groups. This may explain why we found significant
decreases in current MHT only among women up to an
age of 60 years. Results from previous studies regarding
age specific patterns of decline in MHT are conflicting
[21,37,38], but findings very similar to ours have been
reported from the Netherlands [21,38].
In Germany, two studies have previously examined the
association of WHI trial results with MHT use [25,26]. A
randomly selected sample of 10,030 German women 45
to 60 years was contacted in a telephone survey in July
2003, and 59.9% completed an interview on prior MHT
use. Overall, 88.6% of ever-users of MHT were aware of
the WHI study results. Among these, 25.7% of women
indicated having stopped MHT after the WHI study,
whereas 14.2% had already discontinued MHT before the
WHI study [25]. The prevalence of lifetime MHT use
among women participating in this previous study was
35.8% [25], which is consistent with 33.9% of ever-users
within the same age range in our 2003–2004 telephone
survey (data not shown in the results). Estimates regard-
ing the change in prevalence of MHT use could not be
derived from the previous study, as information regarding
duration and time of discontinuation of MHT was not sys-
tematically collected [25]. Within a regional health study
of peri- and postmenopausal women 45–65 years of age,
Clanget and colleagues observed a 16% decline in the
prevalence of current MHT use (35.4% vs. 29.8%)
between April 2000 and February 2003, while the preva-
lence of past MHT use increased accordingly (19.8% vs.
23.5%) [26]. Recruitment following the publication and
media coverage of the WHI trial results extended only over
a few months, which may explain why the observed differ-
ences were much less pronounced than in the present
study.
Few studies have previously investigated the association
of the WHI study results with MHT use according to edu-
cational level, professional status or household income.
Most of these did not find any evidence for a modifying
effect of socioeconomic background [16,17,39]. How-
ever, declines in MHT use in the post-WHI era have been
observed to differ in US study populations of different
educational background, with smaller changes reported in
a less well-educated population of women enrolled in a
Medicaid program [40] than in an unselected national
sample of women [12]. A recent retrospective analysis of
MHT use among women of a British birth cohort found
the reverse; the prevalence of MHT use declined most
among women with lower educational background [23].
Unlike the present study and a recent report from Italy
[17], these authors also found a large decrease in MHT use
among women with cardiovascular risk factors, in partic-
ular obesity and hypertension. These conditions are likely
to correlate with lower social status; multivariable analy-
ses were not performed, hence confounding could explain
the apparent contradiction to our results [23].
We explored several possible explanations for the
observed convergence of MHT use among women of
higher social status with pre-existing patterns among
lower social-status women. First, women from different
social backgrounds may differ with respect to motivation
for MHT use. As observed in our 1997–1999 survey, epi-
demiological studies have consistently found that MHT
users characteristically differ from non-users with respect
to a higher educational or socioeconomic status
[17,41,42], lower BMI [41-44], and more health-con-
scious behaviour, specifically physical activity [41,42,44-
46]. Kuh and colleagues previously suggested that edu-BMC Women's Health 2007, 7:19 http://www.biomedcentral.com/1472-6874/7/19
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cated women are more likely to start MHT for long-term
prevention, as opposed to less-well educated women who
use MHT as a remedy for symptoms and pre-existing
health problems, such as an early menopause or prior hys-
terectomy [47]. Considering the fact that MHT was among
the most heavily promoted 'anti aging' or 'health conserv-
ing' medications prior to the WHI study [11], it is conceiv-
able that women of higher social status were using MHT
mainly for the prevention of chronic conditions in later
life, and would then be more likely to stop treatment fol-
lowing the release of the WHI results [9,36].
Unfortunately, we had no information on reproductive
history and menopausal symptoms, which precluded a
comparison of motivation and indications between MHT
users of different social status in the two surveys. We can
therefore not exclude that higher hysterectomy rates
among women with lower social status confounded our
observation of a larger decline in MHT use in association
with higher social status. There is evidence for an inverse
association between hysterectomy and social status from
several epidemiological studies [48], including a survey
conducted in 2000 among women in one metropolitan
area of West Germany [49]. While these data are not rep-
resentative at the national level, reanalysis of data from an
earlier 1990–1991 national health survey in Germany
showed that a self-reported history of hysterectomy used
to be significantly more common among women of low-
est social status compared to women with intermediate or
highest social status (OR 2.00, 95% CI 1.50–2.67, Robert
Koch-Institute, unpublished data). Hysterectomy rates
were also significantly higher among West vs. East Ger-
man women (25.4% vs. 18.6%, p = .002, for women 40–
69 year-old, Robert Koch-Institute, unpublished data),
which could explain why we observed a consistently
higher prevalence of current MHT use in West vs. East Ger-
many in the present analysis. It is possible that other
health system specific differences between East and West
Germany had a lasting influence on MHT use in the two
parts of Germany. However, we cannot provide data to
support any specific hypotheses. An association between
hysterectomy and continuing MHT use has been reported
by a number of studies, both in Europe and the US
[9,12,24,50], although conflicting results also exist
[25,51]. Consistent with this finding, lower discontinua-
tion rates have been observed among women on estrogen
monotherapy compared to those using estrogen/proges-
tin combinations in the US [9,14-16,35,36] as well as in
European countries [21,24,26].
Our findings concerning the connection between MHT
use and social status may also reflect that social back-
ground influences women's information status on the
risks and benefits of MHT. In their 2003 telephone survey,
Heitmann and colleagues demonstrated a direct relation-
ship between women's social status and their degree of
information about the WHI study results [25]. In the
North American Menopause Society 1998 menopause
survey, women of lowest socioeconomic status were
found to be least likely to have received counselling for
postmenopausal MHT by medical professionals [52]. A
recent nationally representative survey of 40–60-year-old
US women found that less well-educated women were sig-
nificantly less aware of WHI results and the impact of
MHT on major chronic diseases [53]. It remains to be
investigated whether women with lower social status are
less well informed because they are less motivated to seek
information or use different sources of information. It is
also unknown whether health care provider factors (e. g.
sex, age, communication skills or specifics of health care
system organization, access to health care, source of infor-
mation) are relevant. Health care organization as well as
communication of scientific results within medical pro-
fessional societies and coverage of health issues by the
public media differ from country to country. Thus, it is
possible that study results on the risks and benefits of
MHT use had a different impact on specific subgroups of
women in different countries. This may partly explain the
conflicting results of previous reports on post-WHI MHT
use and social status [16,17,39,40].
Strengths and limitations of the present study
Both surveys were independent, highly standardized and
population-based representative national health surveys,
using largely identical core questionnaires and computer-
assisted interview methods. In order to achieve compara-
bility between surveys and to be able to extend the obser-
vations to the population level, survey results were
weighted by a composite demographic weighting factor.
This factor adjusted for deviations in main demographic
characteristics between the study populations and official
population statistics at the time of the specific surveys
(1997–1999 and 2003–2004 respectively); in addition
the factor integrated a comparison with 2003 population
statistics as a common standard for both surveys. Societies
change over time. Thus, survey research needs to be
adjusted for inflation with regard to key socio-demo-
graphic characteristics. We therefore used a construct var-
iable to describe social status, which was computed from
identical component information regarding education,
income and professional status, but was adapted to soci-
etal changes over time. Due to cohort effects, such adjust-
ment will not remove all the differences between
population samples of the same age range compared in
repeat surveys over time. In our study, this was reflected
by the fact that women of the two population samples still
somewhat differed with respect to social status as well as
health-related behaviour. We therefore adjusted for these
variables in multivariable analyses. Previously conducted
non-response analyses demonstrated that participationBMC Women's Health 2007, 7:19 http://www.biomedcentral.com/1472-6874/7/19
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tended to be associated with a younger age and higher
educational background in both surveys, whereas persons
with pre-existing medical conditions were more likely to
be overrepresented only in the 2003–2004 telephone sur-
vey [28,34]. However, the prevalence of pre-existing con-
ditions with relevance to current MHT was similar among
women of both surveys.
Our study has a number of limitations. First, our observa-
tions are only based on measurements at two points in
time, and it would have been much preferable to support
them by being able to assess intervening trends. However,
the only other national health telephone survey con-
ducted between the two surveys analyzed here, did not
collect information on MHT use. Secondly, the 1997–
1999 and 2003–2004 surveys differed with respect to
sampling and interview methods, which could have
biased our results. Most importantly, the validity of our
outcome variable (current MHT use) may differ between
surveys. While information on MHT in 1997–1999 was
obtained in the context of a detailed personal interview on
all current medications, during the 2003–2004 telephone
survey interview women were specifically questioned
about current as well as past MHT use. Thus it is possible,
that MHT users in the first survey were more likely to be
missed, the consequence of which would be an underesti-
mation of initial MHT use and dilution of the difference
between the two surveys. Misclassification with the same
effect of decreasing the difference between survey periods
could also result from over-reporting of current MHT use
in the 2003–2004 survey, for example by women who
had replaced MHT by complementary alternative medi-
cine. As we found a strong overall decline in current MHT
use between the two survey periods, our results would
only be compatible with differential misclassification in
association with lower social status. However, this seems
unlikely, because significantly lower MHT use in associa-
tion with lower social status as observed in the 1997–99
survey has been a consistent finding in previous studies of
MHT [17,41,42], and there is no evidence for selective
over-reporting of current MHT use among women with
low social status.
Conclusion
Between 1998 and 2004 current use of MHT considerably
declined by 40% among women in Germany. While nei-
ther we nor others can prove a direct relationship to the
interim publication and media coverage of results from
the EPT-WHI trial and other studies such as the Million
Women Study, this is suggested by parallel developments
in various countries. Unlike previous reports, we observed
profound differences in user profiles. In particular,
decreases in the prevalence of current MHT use were most
pronounced in women with higher social status. This
resulted in a convergence of current MHT use among high
social-status women with pre-existing patterns of use
among women with low social status. Future studies
should test the hypothesis that women of different social
and cultural backgrounds differ with respect to motiva-
tion and indications of MHT use. International compari-
sons of MHT use and MHT-related health care patterns
would help clarify the respective roles of patient, health
care provider, and health system characteristics when
translating the study results on the risks and benefits of
MHT use into medical practice.
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